

# **INFECTIONS IN EGYPTIAN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS**

## **A STUDY OF AIN SHAMS LUPUS COHORT**

*Thesis*

*Submitted for Partial Fulfillment of the MD Degree*

*In Internal Medicine*

*Presented by*

**Naglaa Afifi Mohammad**

*(M.B.B.Ch. M s c)*

*Under Supervision*

**Prof. Dalia Fayez Mohammad**

*Professor of Internal Medicine and Rheumatology*

*Faculty of Medicine- Ain Shams University*

**Dr. Reem Abd El Moniem Habeeb**

*Assistant Professor of Internal Medicine and Rheumatology*

*Faculty of Medicine -Ain Shams University*

**Dr. Sherin Mohamad Hosney**

*Assistant Professor of Internal Medicine and Rheumatology*

*Faculty of Medicine -Ain Shams University*

**Dr. Shafica Ibrahim Ibrahim**

*Lecturer of Internal Medicine and Rheumatology*

*Faculty of Medicine- Ain Shams University*

*Faculty of Medicine*

*Ain Shams University*

**2014**

# **العدوى في المرضى المصريين المصابين بمرض الذئبة الحمراء**

## **دراسة جماعية عن الذئبة في مستشفيات عين شمس**

رسالة

مقدمة كجزء متمم توطئة للحصول على درجة الدكتوراه في الأمراض الباطنة

مقدمة من

**الطبيبة / نجلاء عفيفي محمد**

ماجستير الباطنة عامه

تحت اشراف

**الأستاذة الدكتورة / داليا فايز محمد**

أستاذ الأمراض الباطنة العامة والروماتيزم  
كلية الطب - جامعة عين شمس

**الدكتورة / ريم عبد المنعم حبيب**

أستاذ مساعد الأمراض الباطنة العامة والروماتيزم  
كلية الطب - جامعة عين شمس

**الدكتور هـ/ شيرين محمد حسني حمزه**

أستاذ مساعد الأمراض الباطنة العامة والروماتيزم  
كلية الطب - جامعة عين شمس

**الدكتور هـ/ شفيقه ابراهيم ابراهيم**

مدرس الأمراض الباطنة العامة والروماتيزم  
كلية الطب - جامعة عين شمس

كلية الطب  
جامعة عين شمس

2014

## *List of Contents*

<i>Title</i>	<i>Page No.</i>
List of tables .....	ii
List of figures.....	vii
List of abbreviations.....	x
Introduction .....	1
Aim of the Work .....	3
<u>Review of Literature</u> .....	4-123
I- Systemic Lupus Erythematosus.....	4
II-Infections in systemic lupus erythematosus.....	72
Patients and Methods.....	124
Results .....	131
Discussion .....	184
Summary and Conclusion .....	202
Recommendation .....	207
References .....	208
Arabic summary.....	--



*List of Tables*  
*Tables of Review*

<i>Tables No.</i>	<i>Title</i>	<i>Pages</i>
<b>Table (1):</b>	International Society of Nephrology—Renal Pathology Society, 2004 Classification of Lupus Glomerulonephritis .....	<b>26</b>
<b>Table (2):</b>	Neuropsychiatric Syndromes Associated With SLE.....	<b>35</b>
<b>Table (3):</b>	American College of Rheumatology Criteria for the Classification of SLE.....	<b>37</b>
<b>Table (4):</b>	The SLICC SLE classification criteria .....	<b>38</b>
<b>Table (5):</b>	Autoantibodies and Clinical Features .....	<b>43</b>
<b>Table (6):</b>	Systemic Lupus Activity Measure (SLAM) Index	<b>45</b>
<b>Table (7):</b>	Summary of factors related to infection susceptibility in SLE .....	<b>80</b>
<b>Table (8):</b>	Helpful features to differentiate between lupus disease activity and infective complications ...	<b>111</b>
<b>Table (9):</b>	Vaccinations to be checked during the initial investigation.....	<b>120</b>

## *Tables of Results*

<i>Tables No.</i>	<i>Title</i>	<i>Pages</i>
<b>Table (1):</b>	Description of lupus related clinical data among all the studied SLE patients (n=200).....	<b>133</b>
<b>Table (2):</b>	Description of different laboratory findings among all the studied SLE patients (n=200).....	<b>135</b>
<b>Table (3):</b>	Description of immunological data among all the studied SLE patients (n=200).....	<b>136</b>
<b>Table (4):</b>	Description of disease activity score as measured by SLAM score among all the studied SLE patients (n=200).....	<b>137</b>
<b>Table (5):</b>	Description of drug therapy among all the studied SLE patients (n=200).....	<b>138</b>
<b>Table (6):</b>	Frequencies of infection/year, complicated and coexisting infections among group A SLE patients.....	<b>139</b>
<b>Table (7):</b>	Frequency of major and minor infection in group A SLE patients (n=110).....	<b>140</b>
<b>Table (8):</b>	Number and Percentage of infection episodes according to the site infection among group A SLE patients (n=110).....	<b>142</b>
<b>Table (9):</b>	Type and number of microorganism in different systems among group A SLE patients.....	<b>144</b>
<b>Table (10):</b>	Total number and percentage of isolated	

	microorganisms among group A SLE patients.....	148
<b>Table (11):</b>	Comparison between the two groups of SLE patients regarding age, sex, and disease duration.....	150
<b>Table (12):</b>	Comparison between the two groups of SLE patients regarding lupus related clinical data.....	151
<b>Table (13):</b>	Comparison between the two groups of SLE patients regarding SLAM score.....	152
<b>Table (14):</b>	Comparison between the two groups of SLE patients regarding active nephritis.....	153
<b>Table (15):</b>	Comparison between the two groups of SLE patients regarding different laboratory findings.....	155
<b>Table (16):</b>	Comparison between the two groups of SLE patients regarding 24h urinary protein and CRP level .....	157
<b>Table (17):</b>	Comparison between the two groups of SLE patients regarding differential WBC count.....	158
<b>Table (18):</b>	Comparison between the two groups of SLE patients regarding C3, C4, anti-DNA, and ANA.....	160
<b>Table (19):</b>	Comparison between the two groups of SLE patients regarding treatment.....	162
<b>Table (20):</b>	Comparison between patients who received	

	azathioprine and patients who didn't receive immunosuppressive regarding the occurrence of infection.....	164
<b>Table (21):</b>	Comparison between patients who received mycophenolate mofetil and patients who didn't receive immunosuppressive regarding the occurrence of infection.....	165
<b>Table (22):</b>	Comparison between patients who received and patients who didn't receive immunosuppressive regarding the occurrence of infection. ....	167
<b>Table (23):</b>	Infection predictor risk factors in SLE patients by multivariate analysis.....	169
<b>Table (24):</b>	EBV and CMV antibody in SLE patients (n=200).....	170
<b>Table (25):</b>	Comparison between EBV -VCA IgM +ve and IgM -ve patients regarding SLAM score.....	171
<b>Table (26):</b>	Comparison between EBV -VCA IgM +ve and IgM -ve patients regarding age, disease duration and different laboratory findings.....	172
<b>Table (27):</b>	Comparison between EBV -VCA IgM +ve and IgM -ve patients regarding C3, C4, anti-ds DNA and differential WBC count .....	174
<b>Table (28):</b>	Comparison between CMV IgM +ve and IgM -ve patients regarding SLAM score.....	176
<b>Table (29):</b>	Comparison between CMV IgM +ve and IgM -ve patients regarding age, disease duration and different laboratory findings.....	177
<b>Table (30):</b>	Comparison between CMV IgM +ve and IgM	



–ve patients regarding C3, C4, anti-ds DNA and differential WBC count.....	<b>179</b>
--	------------

<b>Table (31):</b> Correlation between EBV-VCA and CMV IgM Ab level and age, disease duration, SLAM score, ANA, anti-ds DNA, C3 and C4 among the studied SLE patients (n=200).....	<b>181</b>
--	------------

*List of Figures*  
*Figures of Review*

<i>Figures No</i>	<i>Title</i>	<i>Pages</i>
<b>Figures (1):</b>	Natural history of SLE .....	<b>8</b>
<b>Figures (2):</b>	pathogenic processes, cells and molecules in systemic lupus erythematosus).....	<b>19</b>
<b>Figures (3):</b>	Localized acute cutaneous lupus erythematosus (malar rash).....	<b>20</b>
<b>Figures (4):</b>	Typical discoid LE-round plaques with keratosis, central atrophy and follicular plugging.....	<b>21</b>
<b>Figures (5):</b>	AVN of the femoral head secondary to SLE.....	<b>24</b>
<b>Figures (6):</b>	Mechanisms of current SLE immunotherapies.....	<b>63</b>
<b>Figures (7):</b>	Mechanisms by which infectious agents induce or protect against systemic lupus erythematosus.....	<b>78</b>
<b>Figures (8):</b>	Common impaired processes in SLE associated with increased infection. (A) humoral processes and (B) cell-mediated processes in SLE .....	<b>86</b>

## *Figures of Result*

<i>Figures No</i>	<i>Title</i>	<i>Pages</i>
<b>Figures (1):</b>	Frequencies of infection/year among group A SLE patients.....	<b>140</b>
<b>Figures (2):</b>	Frequency of major and minor infection in group A SLE patients (n=110).....	<b>141</b>
<b>Figures (3):</b>	Number and Percentage of infection episodes according to the site infection among group A SLE patients.....	<b>143</b>
<b>Figures (4):</b>	Type of microorganism in Urinary tract.....	<b>147</b>
<b>Figures (5):</b>	Total number and percentage of isolated microorganisms among group A SLE patients.....	<b>149</b>
<b>Figures (6):</b>	Comparison between the two groups of SLE patients regarding SLAM score.....	<b>153</b>
<b>Figures (7):</b>	Comparison between the two groups regarding nephritis .....	<b>154</b>
<b>Figures (8):</b>	Comparison between the two groups of SLE patients regarding mean WBC.....	<b>156</b>
<b>Figures (9):</b>	Comparison between the two groups of SLE patients regarding mean S. albumin.....	<b>156</b>
<b>Figures (10):</b>	Comparison between the two groups of SLE patients regarding differential WBC count.....	<b>159</b>
<b>Figures (11):</b>	Comparison between the two groups regarding Low C3, low C4 and +Ve anti-DNA. ....	<b>161</b>

<b>Figures (12):</b>	Comparison between the two groups regarding treatment.....	<b>163</b>
<b>Figures (13):</b>	Comparison between patients who received azathioprine and patients who didn't receive immunosuppressive regarding the occurrence of infection.....	<b>165</b>
<b>Figures (14):</b>	Comparison between patients who received mycophenolate mofetil and patients who didn't receive immunosuppressive regarding the occurrence of infection.....	<b>166</b>
<b>Figures (15):</b>	Comparison between patients who received and patients who didn't receive immunosuppressive regarding the occurrence of infection.....	<b>168</b>
<b>Figures (16):</b>	EBV and CMV antibody in SLE patients (n=200).	<b>170</b>
<b>Figures (17):</b>	Correlation between EBV-VCA IgM level and (a) SLAM score, and (b) disease duration.....	<b>182</b>
<b>Figures (18):</b>	Correlation between CMV IgM level and (a) SLAM score, and (b) disease duration.....	<b>183</b>

### *List of abbreviations*

<b>Abb.</b>	<b>Full Name</b>
<b>Abs.....</b>	Antibodies
<b>ACE .....</b>	Angiotensin-converting enzyme
<b>ACR.....</b>	American College Of Rheumatology
<b>AD.....</b>	Autoimmune Diseases
<b>ADA.....</b>	Adenosine Aminase
<b>AHA.....</b>	Autoimmune Hemolytic Anemia
<b>AIIRD .....</b>	Auto-Immune Inflammatory Rheumatic Diseases
<b>ALP .....</b>	Alkaline Posphatase
<b>ALT .....</b>	Alanine Aminotransferase
<b>ANAs.....</b>	Antinuclear antibodies
<b>Anti-CCP ..</b>	Anti- citrullinated Cyclic Peptide
<b>Anti-Sm ....</b>	Anti- Smooth Muscle
<b>APC .....</b>	Antigen Presenting Cell
<b>APS .....</b>	Antiphospholipid Syndrome
<b>AST .....</b>	Aspartate Aminotransferase
<b>AVN.....</b>	Avascular Necrosis
<b>AZA .....</b>	Azathioprine
<b>BAFF .....</b>	B cell–activating factor
<b>BCG .....</b>	Bacillus Calmette–Guérin
<b>BILAG .....</b>	The British Isles Lupus Assessment Group Index
<b>BLyS .....</b>	B lymphocyte stimulator
<b>BUN .....</b>	Blood Urea Nitrogen
<b>C1q .....</b>	Complement 1q
<b>C3.....</b>	Complement 3
<b>C4.....</b>	Complement 4
<b>CAP .....</b>	Community-Acquired Pneumonia

<b>CBC .....</b>	Complete Blood Count
<b>CMV .....</b>	Cytomegalovirus
<b>CNS .....</b>	Central nervous system
<b>CRP .....</b>	C-Reactive Protein
<b>CsA .....</b>	Cyclosporine A
<b>CT .....</b>	Computed Tomography
<b>CYC .....</b>	Cyclophosphamide
<b>DC .....</b>	Dendritic cells
<b>DHEA .....</b>	Dehydroepiandrosterone
<b>DMARDS....</b>	Diseas Modefying Anti Rheumatic Drugs
<b>DNA .....</b>	Deoxyribonucleic Acid
<b>dsDNA .....</b>	Double-Stranded DNA
<b>EBV .....</b>	Epstein Barr Virus
<b>EBV-VCA ..</b>	EBV-Viral Core Antigen
<b>ELISA .....</b>	Enzyme-Linked Immunoabsorbent Assay
<b>ESR .....</b>	Erythrocyte Sedimentation Rate
<b>ESRD .....</b>	End stage renal disease
<b>EULAR.....</b>	The European League Against Rheumatism
<b>FcγR .....</b>	Fc-Gamma Receptors
<b>FDA .....</b>	Food and Drug Administration
<b>GCs .....</b>	Glucocorticoids
<b>G-CSF.....</b>	Granulocyte- Colony Stimulating Factor
<b>HAV .....</b>	Hepatitis A-virus
<b>HBV .....</b>	Hepatitis B-Virus
<b>HCQ .....</b>	Hydroxychloroquine
<b>HCV .....</b>	Hepatitis C-Virus

<b>HIV</b> .....	Human Immune Deficiency Virus
<b>HLA</b> .....	Human Leukocytic Antigen
<b>Hpf</b> .....	High Power Field
<b>HPV</b> .....	Human Papilloma Virus
<b>hsCRP</b> .....	High-sensitivity CRP
<b>HZ</b> .....	Herpes Zoster
<b>ICU</b> .....	Intensive Care Unit
<b>IFI</b> .....	Invasive Fungal Infection
<b>Ig</b> .....	Immunoglobulin
<b>IL</b> .....	Interleukin
<b>INF</b> .....	Interferon
<b>INH</b> .....	Isoniazid
<b>ISN/RPS</b> ..	International Society of Nephrology and Renal Pathology Society
<b>ITP</b> .....	Idiopathic thrombocytopenic purpura
<b>IVIG</b> .....	Intravenous Immunoglobulins
<b>KCS</b> .....	Keratoconjunctivitis sicca
<b>Kg</b> .....	Kilogram
<b>LDH</b> .....	Lactat Dehydrogenase
<b>LGN</b> .....	Lupus Glumerulonephritis
<b>LKM</b> .....	Liver Kidney Microsomal
<b>LMI</b> .....	Listeria Monocytogenes Infection
<b>LN</b> .....	Lupus Nephritis
<b>MAC</b> .....	Membrane Attack Complex
<b>MBL</b> .....	Mannose-Binding Lectin
<b>mDC</b> .....	Myeloid Dendritic Cells